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I M M U N O L O G Y
IL-27 signaling activates skin cells to induce 
innate antiviral proteins and protects against Zika 
virus infection
Jeffery T. Kwock1, Chelsea Handfield1, Jutamas Suwanpradid1, Peter Hoang1, 
Michael J. McFadden2, Kevin F. Labagnara2, Lauren Floyd1, Jessica Shannon1,3, Ranjitha Uppala4,  
Mrinal K. Sarkar4, Johann E. Gudjonsson4, David L. Corcoran5, Helen M. Lazear6, 
Gregory Sempowski7,8, Stacy M. Horner2, Amanda S. MacLeod1,2,3*
In the skin, antiviral proteins and other immune molecules serve as the first line of innate antiviral defense. Here, 
we identify and characterize the induction of cutaneous innate antiviral proteins in response to IL-27 and its func-
tional role during cutaneous defense against Zika virus infection. Transcriptional and phenotypic profiling of 
epidermal keratinocytes treated with IL-27 demonstrated activation of antiviral proteins OAS1, OAS2, OASL, and 
MX1 in the skin of both mice and humans. IL-27–mediated antiviral protein induction was found to occur in a 
STAT1- and IRF3-dependent but STAT2-independent manner. Moreover, using IL27ra mice, we demonstrate a 
significant role for IL-27 in inhibiting Zika virus morbidity and mortality following cutaneous, but not intrave-
nous, inoculation. Together, our results demonstrate a critical and previously unrecognized role for IL-27 in cutane-
ous innate antiviral immunity against Zika virus.
INTRODUCTION
Zika virus (ZIKV) is an emerging pathogen that is transmitted to 
humans via a mosquito bite, and it can lead to congenital infection 
and neurodevelopmental defects if transmitted in utero, as well as 
Guillain-Barré syndrome in adults (1). Given that ZIKV inocula-
tion begins with a mosquito bite, the skin serves as the first line of 
defense against systemic dissemination of ZIKV. One of the earliest 
innate immune defenses against viral infection is the production of 
antiviral proteins (AVPs), a specific subset of antimicrobial pro-
teins (AMPs) that have activity against viruses (2–4). While the 
innate immune circuits that regulate antibacterial peptide and protein 
production are relatively well defined, little is known about the role 
and regulation of AVPs in the skin.
AVPs, including MX dynamin-like GTPase (guanosine triphos-
phatase) (MX) and the oligoadenylate synthase (OAS) family of 
molecules, are critical propagators of the cellular antiviral state. 
Previous studies have largely focused on induction of AVPs by inter-
ferons (IFNs), which is why these proteins are often referred to as 
IFN-stimulated genes (ISGs) (5). However, many viruses, including 
skin-tropic herpes simplex virus (HSV) and vaccinia virus, as well 
as mosquito-borne viruses such as dengue virus and ZIKV, have 
evolved escape mechanisms to block IFN and downstream signal-
ing targets to escape host immunity (6, 7). Furthermore, while 
IFN- is used to treat viral illnesses such as hepatitis B and cancers, 
including chronic myeloid leukemia (8), IFN- is associated with 
an extensive adverse effect profile, including neurotoxicity, nephro-
toxicity, and potentially fatal cytokine storm (9). Therefore, identi-
fication of factors to enhance innate antiviral immunity that are not 
dependent on IFN signaling may lead to the development of poten-
tial novel therapeutics against viral diseases.
Given the critical role of keratinocytes in skin antimicrobial host 
defense (3, 10–16), we sought to investigate the expression, regulation, 
and function of keratinocyte innate AVPs by the IFN-independent 
cytokine, interleukin-27 (IL-27), and the impact this signaling path-
way has on in vitro and in vivo ZIKV infection.
IL-27 is a member of the IL-12 superfamily of cytokines (17, 18). 
IL-27 is a heterodimer composed of p28 and Epstein-Barr virus– 
induced 3 (EBI3), and it binds to the heterodimeric IL-27 receptor, 
composed of IL27RA and GP130 (19, 20). IL27RA is highly expressed 
on T cells; therefore, studies have largely focused on the biological 
function of IL-27 on T cells (21–28). For instance, IL-27 appears to 
have an inhibitory role on inflammation in the context of parasitic 
infections such as Toxoplasma gondii, Trypanosoma cruzi, Leishmania, 
or Plasmodium and Il27ra−/− mice phenocopy mice lacking IL-10 
(19, 29, 30). However, IL-27 signaling is also capable of acting on 
naïve CD8+ T cells to enhance the generation of cytotoxic T lym-
phocytes (31), maintain plasmacytoid dendritic cells (32), and block 
HIV viral replication in CD4+ T cells (33).
We describe that IL-27 signaling leading to AVP production is 
IL27RA, STAT1 (signal transducers and activators of transcription 1), 
and IRF3 (interferon regulatory factor 3) dependent, but STAT2 
independent. Functionally, IL-27 significantly suppressed ZIKV 
infection in human keratinocytes. Small interfering RNA (siRNA) 
and CRISPR-Cas9 gene editing, as well as mouse genetic knockout 
(KO) approaches, revealed that IL-27–mediated OAS2 signaling is 
STAT1 and IL27RA dependent, but STAT2, TYK2, and IFNAR1 
independent. The in vivo relevance of IL-27 signaling was further 
demonstrated in murine infection models, where concurrent loss of 
Ifnar1 and Il27ra (Ifnar1−/−Il27ra−/−) resulted in significantly greater 
ZIKV-induced morbidity and mortality after subcutaneous virus 
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inoculation compared with IL27ra. IL-27 conferred no protection 
against intravenous ZIKV infection, demonstrating the skin-specific 
activity of IL-27. These observations highlight IL-27 as a potential novel 
therapeutic agent against ZIKV by illustrating its abilities to enhance 
the skin’s own innate antiviral defenses.
RESULTS
IL-27 induces the expression of AVPs in keratinocytes 
to mediate antiviral function
Recently, our laboratory has demonstrated that IL-27 plays a key role in 
wound healing by inducing epidermal proliferation of keratinocytes 
and changing the expression of keratins and differentiation markers 
in these cells (17). Follow-up experiments where IL-27 was used to 
stimulate primary human keratinocytes revealed that keratinocytes 
respond to IL-27 by modulating expression of numerous genes, includ-
ing many that encode AVPs. To evaluate IL-27’s ability to regulate 
gene expression, we treated human epidermal keratinocytes with 
IL-27 and analyzed the expression of multiple genes using a DNA 
microarray. We found that recombinant human IL-27 potently in-
duces the expression of multiple keratinocyte AVPs, including OAS1, 
OAS2, OAS3, OASL, and MX1 (Fig. 1A), additional ISGs containing 
interferon gamma activated site (GAS) motifs and/or IFN-stimulated 
response element (ISRE) motifs, such as IFN regulatory factor 1 
(IRF1), IFN- induced helicase C domain–containing protein 1 (IFIH1, 
MDA5), IFN-stimulated exonuclease gene 20 (ISG20), as well as IL-32, 
and Basic leucine zipper transcription factor, ATF-like 2 (BATF2) 
[suppressor of Activator Protein-1 (AP-1), regulated by IFN], and 
multiple genes from the guanylate-binding protein (GBP) family.
To confirm that IL-27 induces the expression of AVPs, we stim-
ulated human keratinocytes with IL-27 for 24 hours and found a 
significant increase in the mRNA expression of OAS1, OAS2, OAS3, 
OASL, and MX1 (Fig. 1, B and C). We also show confirmation of MX1 
and OAS2 on the protein level (Fig. 1D). Notably, IL-27 failed to 
induce the expression of human -defensin 2 (HBD2), an AMP whose 
effects are predominantly antibacterial, rather than antiviral (Fig. 1B) 
(34). Since IL-27 is a member of the IL-12 family of cytokines, we 
sought to determine whether other IL-12 family members could also 
induce AVPs in keratinocytes. Although we observed that both IL-27 
and IL-23 significantly induced the production of OAS2, the induc-
tion of OAS2 by IL-23 was less than that of IL-27 at both 16 and 
24 hours after stimulation and, in fact, decreased at 24 hours after 
stimulation (Fig. 1C). Other IL-12 family cytokines (IL-6, IL-12, and 
IL-35) failed to induce AVP expression. Because AVPs have classi-
cally been shown to be regulated by IFNs (5), we compared the ability 
of IL-27 to induce AVPs to that of a type I IFN (IFN-) and type II 
IFN (IFN-). As expected, keratinocytes stimulated with IFN- showed 
a significant increase in OAS2 expression at multiple time points, 
and IFN- induced a significant increase in OAS2 expression at 
16 hours after stimulation (Fig. 1E). Notably, at a concentration of 
50 U/ml, both IFN-– and IFN-–mediated expression of OAS2 was 
similar in terms of fold change to IL-27– induced OAS2 expression. 
We next sought to determine whether IL-27 treatment of keratino-
cytes was associated with cytotoxicity. We found that neither IL-27 
nor IFNs tested here were associated with any major cytotoxicity in 
primary human keratinocytes when delivered at concentrations that 
significantly increase AVP production (fig. S1, A and B).
To define the signaling pathway by which IL-27 drives AVP 
expression in human keratinocytes, we next evaluated the effect of 
IL-27 in the presence or absence of nucleic acid agonists of pattern 
recognition receptor (PRR) signaling, molecules that play a key role 
in activating pathways that produce IFNs and ISGs (35, 36). Since 
previous studies have shown that PRR signaling leads to AVP pro-
duction, and our current research suggested that IL-27 also gener-
ates AVPs, we wanted to determine whether the presence of PRR 
agonists would lead to an increase in AVP production by IL-27. 
Intracellular (transfected) low–molecular weight poly I:C (poly I:C 
LMW) increased OAS2 expression in human keratinocytes, and the 
addition of IL-27 further enhanced OAS2 expression (Fig. 1F). Other 
Toll-like receptor (TLR) ligands, such as 5′PPPdsRNA (a RIG-I 
ligand), 2′3′cGAMP (a cGAS ligand), and imiquimod (IMQ) [a single- 
stranded RNA (ssRNA) analog that serves as a TLR 7 agonist], did 
not induce potent OAS2 expression in the absence of IL-27. However, 
IL-27 was still capable of inducing OAS2 expression in the presence 
of these ligands (Fig. 1F and fig. S1C). Together, our data suggest 
that IL-27 not only activates OAS2 transcription but also enhances 
other innate antiviral immune pathways, as seen by the additive 
effect that IL-27 exerts on poly I:C–mediated OAS2 expression.
We next sought to determine whether IL-27 would induce cuta-
neous AVP production in vivo. Injection of recombinant murine IL-27 
into the skin of ears of C57BL6/J wild-type mice resulted in a potent 
induction of the AVPs Oas1, Oas2, Oasl1, and Oasl2 (Fig. 1G), a pattern 
of expression that mirrored the antiviral gene signature observed 
upon stimulation of human keratinocytes with IL-27 (Fig. 1B).
The ability of IL-27 to activate AVPs, including OAS family 
members known to play a role as antiviral effector proteins of RNA 
viruses (37) in keratinocytes, both independently and in conjunc-
tion with nucleic acid signaling, suggested to us that IL-27 may 
functionally mediate antiviral defenses against RNA viruses. Virus 
transmission and infection of the skin is frequently facilitated 
through microinjuries associated with skin barrier dysfunction, 
trauma, or mosquito bites (3). We found that human keratinocytes 
treated with IL-27 were less susceptible to infection by Sendai virus 
and ZIKV (Fig. 1, H and I). IL-27 inhibited infection of keratino-
cytes by Sendai virus, a negative sense ssRNA paramyxovirus, at 
both 100 hemagglutination units (HAUs) and 20 HAUs (Fig. 1H). 
For ZIKV, at a multiplicity of infection of 1 and 10, IL-27 also inhib-
ited viral keratinocyte infection (Fig. 1I), while IFN- was used as a 
positive control. Together, our data suggest that IL-27’s effect on 
human keratinocytes is broadly antiviral.
IL-27 induces OAS2 in an IL27RA/STAT1/IRF3-dependent 
and IFNAR1/TYK2/STAT2- and IFNGR1-independent manner
Given the similarities between IL-27–mediated AVPs and the clas-
sical IFN-mediated production of ISGs, we next determined whether 
IL-27 requires IFN signaling to induce OAS2. We used siRNA 
transfection to knock down specific genes in primary human kerat-
inocytes and stimulated these cells with IL-27. Successful knockdown 
of target genes was confirmed using quantitative reverse transcrip-
tion polymerase chain reaction (qRT-PCR) (fig. S2). Knockdown of 
IL27RA and STAT1 significantly inhibited IL-27–mediated OAS2 
expression, whereas knockdown of IFNGR1, STAT2, and IFNAR1 
did not inhibit OAS2 expression (Fig. 2A). Knockdown of STAT2 
and IFNAR1 increased IL-27–mediated OAS2 expression. We next 
used siRNA to target numerous genes associated with viral sensing 
and response pathways, including the type I IFN and RIG-I–like 
receptor signaling pathways. Knockdown of JAK1, IRF1, IRF3, IRF7, 
TRAF6, TRIM25, BATF2, IFIH1 (MDA5), and MAP3K7 (also known 
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Fig. 1. IL-27 Induces the expression of AVPs in keratinocytes and inhibits ZIKV infection in vitro and in vivo. (A) DNA microarray of normal human epidermal kerat-
inocytes treated for 24 hours with recombinant human IL-27 (100 ng/ml). (B) Quantitative PCR (qPCR) analysis examining the expression of multiple AVPs by primary 
human keratinocytes treated with IL-27 (100 ng/ml). The relative fold change for each condition was determined on the basis of OAS2 expression compared with non-
treated cells. n = 6 biological replicates. (C) qPCR analysis examining the expression of OAS2 by primary human keratinocytes stimulated with 100 ng/ml of IL-6, IL-12, IL-23, 
IL-27, or IL-35 for 6, 16, and 24 hours. The relative fold change for each condition was determined on the basis of OAS2 expression compared with nontreated cells. n = 3 
biological replicates. (D) Representative immunofluorescence staining showing MX1 and OAS2 (red) and Hoechst (blue) in NHEKs stimulated with rhIL-27 (100 ng/ml) for 
48 hours. Original magnification, ×400 (50 m). (E) qPCR analysis examining the expression of OAS2 by primary human keratinocytes stimulated with IL-27 (100 ng/ml), 
IFN- (50 U/ml), or IFN- (50 U/ml) for 3, 6, or 16 hours. The relative fold change for each condition was determined on the basis of OAS2 expression compared with non-
treated cells. n = 3 biological replicates. (F) qPCR analysis examining the expression of OAS2 by primary human keratinocytes transfected with 5′PPPdsRNA (100 ng/ml), 
poly I:C LMW, and 2′3′cGAMP and simultaneously stimulated with IL-27 (100 ng/ml) for 24 hours. The relative fold change for each condition was determined on the basis 
of OAS2 expression compared with non–IL-27–treated cells. n = 3 biological replicates. Trans Rgt, Transfection Reagent. (G) qPCR analysis examining the expression of 
indicated AVPs in response to subcutaneous injection of recombinant murine IL-27 (100 ng/ml) into the right ear of C57BL6/J mice. Tissue from both the treated right ear 
and nontreated left ear was harvested at 18 hours after injection. The relative fold change of each AVP in rIL-27–treated ears to DPBS-treated ears in both the epidermis 
and dermis. n = 3 mice. ns, not significant. (H) Quantification of Sendai virus envelope protein immunostaining of primary human keratinocytes pretreated for 24 hours 
with recombinant human IL-27 (100 ng/ml) and infected for 48 hours with Sendai virus at 100 and 20 HAU. Percentage of cells infected in IL-27–treated keratinocytes was 
compared with the percentage of cells infected in nontreated keratinocytes. n = 4 technical replicates in three separate experiments. (I) Focus-forming assay of supernatants from 
primary human keratinocytes pretreated with recombinant human IL-27 (100 ng/ml) or IFN- (50 U/ml) for 4 hours and infected with Zika virus (Dakar strain) at 1 or 10 mul-
tiplicity of infection (MOI) for 48 hours. Titers were calculated as focus-forming units per milliliter and graphed as percent of Ctrl (Control, no cytokine treatment). To test 
for statistical significance, a two-tailed Student’s unpaired t test (B and E to H) or two-way analysis of variance (ANOVA) with Tukey’s multiple comparison test (C and D) 
was performed using GraphPad Prism software. Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant.
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as TAK1), significantly inhibited OAS2 transcription upon IL-27 
stimulation, suggesting that IL-27–mediated OAS2 production 
requires these signaling molecules (Fig. 2B). In contrast, knock-
down of JAK2, AZI2 (NAP1), TBK1, IKBKE, MAVS, and TLR3 
did not suppress OAS2 transcription following IL-27 stimulation in 
keratinocytes.
To further investigate STAT1 signaling upon IL-27 stimulation, 
we treated primary human keratinocytes with IL-27 and analyzed 
these cells at different time points after stimulation and also stained 
for p-STAT1 and p-STAT2. p-STAT1 was found to translocate to 
the nucleus as early as 15 min after IL-27 treatment (Fig. 3A). 
Although absolute number of cells demonstrating nuclear p-STAT1 
translocation remained relatively unchanged from 15 to 90 min 
after IL-27 stimulation, the intensity of staining decreased from 
30 to 90 min (fig. S3A). Conversely, p-STAT2, a key component of 
the p-STAT1/p-STAT2 heterodimer required for classical type I 
IFN signaling, failed to translocate to the nucleus of human kerati-
nocytes in response to IL-27 at all time points examined, whereas 
IFN- used as a positive control did induce p-STAT2 translocation 
(Fig. 3B and fig. S3B). The rapid and transient nuclear translocation 
of p-STAT1 in response to IL-27 in the absence of p-STAT2 trans-
location supports the view that IL-27 activates a STAT1-dependent 
pathway distinct from the STAT1-STAT2 heterodimers activated 
by type I IFN signaling. To further confirm that the IL-27–AVP 
pathway is STAT1 dependent, but independent of type I IFN signal-
ing, we next examined human keratinocytes using CRISPR-Cas9 
KO of STAT1, STAT2, and TYK2, known mediators of the type I 
IFN pathway. Figure S3C shows the Sanger sequence for the STAT1, 
STAT2, and TYK2 KO keratinocytes, confirming specific CRIPSR-
Cas9 targeting. We observed that IL-27–mediated OAS2 production 
was dependent on STAT1, but not STAT2 or TYK2, confirming that 
IL-27–mediated OAS2 production is STAT1 dependent, but STAT2 
and TYK2 independent (Fig. 3C).
IRF3 plays a key role in the MAVS and the STING/TBK1 signal-
ing cascade downstream of TLR3 and additional TLRs, as well as 
additional RNA and DNA sensors (38–40). Since we demonstrated 
that IL-27 signaling is dependent on IRF3 and that IL-27 enhances poly 
I:C–mediated production of AVPs, we wanted to examine whether 
IRF3 was activated in response to IL-27 signaling. We found that 
IRF3 translocates to the nucleus within 45 min in primary human 
keratinocytes stimulated with IL-27 (Fig. 3D). The percentage of 
cells exhibiting IFRF3 nuclear translocation in response to IL-27 was 
similar to the percentage of cells exhibiting nuclear translocation in 
response to transfected dsRNA, which was used as positive control.
Since we found that STAT1 signaling is required for IL-27– 
mediated expression of OAS2 in keratinocytes, we next assessed 
whether STAT1 was required for the in vivo antiviral activity toward 
ZIKV. We found that Stat1KO mice succumbed to ZIKV infection 
through both intravenous (Fig. 4A) and subcutaneous inoculation 
routes (Fig. 4B) at 13 days after infection, whereas wild-type 129S6 
mice experienced no mortality (Fig. 4, A and B). Genetic KO of 
Stat1 led to a gradual decline in weight before death in mice that 
were infected with ZIKV via either intravenous (Fig. 4C) or subcu-
taneous (Fig. 4D) injection. In addition, Stat1KO mice infected with 
ZIKV experienced similar clinical disease signs to infected Ifnar1KO 
and Ifnar1/Il27ra double KO (dKO) mice (fig. S4). Thus, our work is 
in agreement with previous data, which demonstrated that Stat1KO 
mice are susceptible to ZIKV infection (41, 42).
IL-27 signaling reduces mortality and weight loss 
due to ZIKV infection in the absence of type I IFN signaling
STAT1 is a key regulatory molecule in both IL-27 and IFN signal-
ing. Having observed that IL-27 can inhibit viral infection in cell 
culture and that STAT1 signaling is critical to antiviral competence 
in mice, we sought to determine the role that IL-27 and type I IFNs 


















































































































































Fig. 2. IL-27 enhances the expression of AVPs in a STAT1-/IL27RA-dependent and STAT2-/IFNAR1-/IFNGR1-independent manner. (A) qPCR analysis examining the 
expression of OAS2 by primary human keratinocytes transfected with siRNA of STAT1, STAT2, IFNGR1, IL27RA, and IFNAR1 for 5 hours and subsequently stimulated with 
IL-27 (100 ng/ml) for 24 hours. To determine statistical significance, the OAS2 expression of siRNA-transfected cells treated with IL-27 was compared with the OAS2 
expression of IL-27–treated cells transfected with an siRNA control. n = 3 biological replicates. (B) qPCR analysis examining the expression of OAS2 by primary human 
keratinocytes transfected with siRNA of immune signaling molecules associated with type I IFN, RIG-I, or MDA5 signaling for 5 hours and subsequently stimulated with 
IL-27 (100 ng/ml) for 24 hours. To determine statistical significance, the OAS2 expression of siRNA-transfected cells treated with IL-27 was compared with the OAS2 
expression of IL-27–treated cells transfected with an siRNA control. n = 3 biological replicates. To test for statistical significance, two-way ANOVA with Tukey’s multiple 
comparison test (A and B) was performed using GraphPad Prism software. Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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Ifnar1KO, and Ifnar1/Il27ra dKO mice bred on a B6 background 
were infected with ZIKV subcutaneously, and mortality, weight, and 
disease signs were measured over 12 days after infection. Although 
wild-type B6 mice are uniformly resistant to ZIKV, Ifnar1KO mice 
are highly susceptible (42). No mortality or changes in weight were 
observed in either wild-type mice or Il27raKO mice, regardless of 
route of infection (Fig. 5, A to D). Notably, 100% of Ifnar1/Il27ra 
dKO mice succumbed to subcutaneous ZIKV inoculation, but only 
50% of Ifnar1KO mice had died at 13 days after infection, identify-
ing a protective role for IL-27 in controlling ZIKV infection (Fig. 5A). 
While we could not detect any differences in the viral titers in the 
serum from Ifnar1/Il27ra dKO compared with Ifnar1KO mice 2 days 
after infection (fig. S5), Ifnar1/Il27ra dKO mice significantly 
exhibited greater weight loss than Ifnar1KO starting at day 5 after 
injection (Fig. 5C). In contrast, intravenous injection of ZIKV led 
to 100% mortality by 10 days after infection and significant de-
creases in weight in both Ifnar1KO and Ifnar1/Il27ra dKO mice 
(Fig. 5, B and D). Significant changes in both weight and mortality in 
Ifnar1/Il27ra dKO mice compared with Ifnar1KO mice in response 
to subcutaneous, but not intravenous, ZIKV infection suggested 
that cutaneous IL-27 signaling specifically may play a protective 
role against ZIKV- associated mortality in the absence of IFN 
signaling.
IL-27 signaling reduces the occurrence and severity 
of neurological disease signs due to ZIKV infection 
in the absence of type I IFN signaling
Having observed that cutaneous IL-27 signaling reduces mortality 
from ZIKV infection in the absence of IFN signaling, we next 
sought to determine whether IL-27 signaling was protective against 
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Fig. 3. Rapid and transient nuclear translocation of p-STAT1, but not p-STAT2, is characteristic of IL-27 signaling. (A) Quantification of immunofluorescence staining 
for p-STAT1 (Cy3) in primary human keratinocytes treated with a time course of 100 ng/ml of IL-27 or 50 U/ml of IFN- for the indicated times. Nuclear translocation was 
quantified by examining five different fields per slide. The nuclear translocation (%) at each treated time point was compared with the nuclear translocation (%) of the 
nontreated control. n = 3 biological replicates. IgG, immunoglobulin G. (B) Quantification of immunofluorescence staining for p-STAT2 (Cy3) in primary human keratino-
cytes treated with a time course of 100 ng/ml of IL-27 or 50 U/ml of IFN- for the indicated times. Nuclear translocation was quantified by examining five different fields 
per slide. The nuclear translocation (%) at each treated time point was compared with the nuclear translocation (%) of the nontreated control. n = 3 biological replicates. 
No stim, No stimulation. (C) qPCR analysis examining the expression of OAS2 in immortalized human keratinocytes with CRISPR-Cas9 KO of STAT1, STAT2, and TYK2 treat-
ed for 6 and 24 hours with recombinant human IL-27 (100 ng/ml). Each experimental condition was compared with the non-CRISPR control. n = 3 biological replicates. 
(D) Immunofluorescence staining for IRF3 (Cy3) in primary human keratinocytes treated for 45 min with 100 ng/ml of IL-27 or poly I:C LMW. Nuclear translocation was 
quantified by examining five different fields per slide. The nuclear translocation (%) for both IL-27 and poly I:C was compared with the nuclear translocation (%) of the non-
treated control. n = 3 biological replicates. To test for statistical significance, a two-tailed Student’s unpaired t test (A to C) or two-way ANOVA with Tukey’s multiple comparison 
test (D) was performed using GraphPad Prism software. Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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the disease signs commonly associated with ZIKV infection in 
Ifnar1−/− mice. Constitutional symptoms such as scruffy fur and 
mild central nervous system weaknesses that herald subsequent 
substantial neurological signs appeared earlier in Ifnar1/Il27raKO 
compared with Ifnar1KO mice, manifesting as early as 5 days after 
infection (Fig. 6). Beginning as early as 7 days after infection, a 
greater percentage of Ifnar1/Il27ra dKO mice began to exhibit 
neurological signs compared with Ifnar1KO mice, with a larger 
number of Ifnar1/Il27raKO mice continuing to exhibit neurological 
signs until succumbing at day 10 after infection via the subcutaneous 
route (Fig. 6). Together, the increased morbidity and mortality 
seen in Ifnar1/Il27ra dKO mice following subcutaneous ZIKV 
infection compared with Ifnar1KO mice suggested that cuta-
neous IL-27 signaling may play a relevant and previously un-
known role in inhibiting ZIKV infection in the skin and may affect 
neurological symptoms. Intact IL-27 signaling may therefore 
serve a protective antiviral role, even in the absence of type I IFN 
signaling.
DISCUSSION
There is an emerging body of evidence that suggests proinflamma-
tory cytokines mediate the production of AMPs (10, 43). Here, we 
found that keratinocytes generate AVPs including OAS1, OAS2, 
OASL, and MX1 in response to IL-27. In vivo, IL-27 demonstrates a 
protective function against subcutaneous ZIKV infection in mice in 
the absence of type I IFN signaling.
Recent studies demonstrating that ZIKV has developed mecha-
nisms to inhibit type I IFN signaling (44) highlight the need to in-
vestigate alternative pathways that may suppress ZIKV infection, 
which remains an infectious disease concern in the Americas and 
elsewhere (45, 46), with the potential to cause severe birth defects 
(47) and neurological symptoms (48), ZIKV is an emerging pathogen 
that is transmitted to humans via mosquito bites. ZIKV evades the
IFN-mediated antiviral response in mice with the help of several
nonstructural proteins, such as NS1 and NS4B. NS1 and NS4B have 
been shown to inhibit IFN- signaling at the level of TANK-binding 
kinase 1 (49) and NS5, which inhibits STAT2 (44). Thus, in vivo
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Fig. 4. STAT1 signaling plays a key role in antiviral defense against Zika virus in vivo. (A) Survival curve of 129S6 (WT) and Stat1KO mice injected intravenously (IV) 
with Zika virus (HPF2013 strain). n = 5 mice (129S6) and 5 mice (Stat1KO) per experimental group. (B) Survival curve of 129S6 (WT) and Stat1KO mice injected subcutane-
ously (SC) with Zika virus (HPF2013 strain). n = 9 mice (129S6) and 14 mice (Stat1KO) per experimental group. (C) Line graph detailing percentage of initial weight in 129S6 
(WT) and Stat1KO mice injected intravenously with Zika virus (HPF2013 strain). The percentage of initial weight of wild-type (WT) mice was compared with the percentage 
of initial weight of Stat1KO at each time point. n = 5 mice (129S6) and 5 mice (Stat1KO) per experimental group. (D) Line graph detailing percentage of initial weight in 
129S6 (WT) and Stat1KO mice injected SC with Zika virus (HPF2013 strain). The percentage of initial weight of WT mice was compared with the percentage of initial weight 
of Stat1KO at each time point. n = 9 mice (129S6) and 14 mice (Stat1KO) per experimental group. To test for statistical significance, a Mantel-Cox test (A and B) or a two-
tailed Student’s unpaired t test (C and D) was performed using GraphPad Prism software. Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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mouse infections necessitate the use of Ifnar1−/− mice (42). However, 
type I IFN signaling has recently been associated with increased risk 
for fetal demise in mice infected with ZIKV (50). Therefore, identi-
fication of innate antiviral immune factors that are not dependent 
on IFN signaling may lead to the development of therapeutics 
against ZIKV and other viruses. When comparing Ifnar1/Il27ra dKO 
mice to Ilfnar1KO mice, the increased morbidity and mortality seen 
in Ifnar1/Il27ra dKO mice following subcutaneous ZIKV infection 
compared with Ilfnar1KO mice suggested that IL-27 signaling may 
play a relevant and previously unknown role in inhibiting ZIKV 
infection. Although the pathogenesis of ZIKV infection is not fully 
understood, it is currently thought that the skin is the first site of 
inoculation and viral replication, given that human primary fibro-
blasts, epidermal keratinocytes, and immature dendritic cells have 
been shown to be permissive to ZIKV infection and replication and 
that other flaviviruses are first inoculated into the skin (51, 52). Sub-
sequently, the virus spreads to the draining lymph node, where it 
replicates, leading to viremia and hematogenous spread to other 
tissues in the body. Given that we observed that subcutaneous, but not 
intravenous, inoculation of ZIKV in dKO resulted in the amelioration 
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Fig. 5. IL-27 signaling reduces in vivo mortality and weight loss due to Zika virus infection in the absence of type I IFN signaling. (A) Survival curve of B6 (WT), 
Ifnar1KO, Il27raKO, and Ifnar1/Il27ra dKO injected subcutaneously (SC) with 104 Zika virus (HPF2013 strain). n = 19 mice (B6), 23 mice (Il27raKO), 22 mice (Ifnar1KO), and 
30 mice (Ifnar1/Il27ra dKO) per experimental group. (B) Survival curve of B6 (WT), Ifnar1KO, Il27raKO, and Ifnar1/Il27ra dKO injected intravenously (IV) with 104 Zika virus 
(HPF2013 strain). n = 7 mice (B6), 13 mice (Il27raKO), 13 mice (Ifnar1KO), and 27 mice (Ifnar1/Il27ra dKO) per experimental group. (C) Line graph detailing percentage of 
initial weight in B6 (WT), Ifnar1KO, Il27raKO, and Ifnar1/Il27ra dKO mice injected SC with Zika virus (HPF2013 strain). The percentage of initial weight of WT mice was 
compared with the percentage of initial weight of each genotype at each time point. n = 19 mice (B6), 23 mice (Il27raKO), 22 mice (Ifnar1KO), and 30 mice (Ifnar1/Il27ra 
dKO) per experimental group. (D) Line graph detailing percentage of initial weight in B6 (WT), Ifnar1KO, Il27raKO, and Ifnar1/Il27ra dKO mice injected intravenously with 
Zika virus (HPF2013 strain). The percentage of initial weight of WT mice was compared with the percentage of initial weight of each genotype at each time point. n = 7 
mice (B6), 13 mice (Il27raKO), 13 mice (Ifnar1KO), and 27 mice (Ifnar1/Il27ra dKO) per experimental group. To test for statistical significance, a Mantel-Cox test (A and B) or 
a two-tailed Student’s unpaired t test for each time point (C and D) was performed using GraphPad Prism software. Data are means ± SEM. ***P < 0.001.
Kwock et al., Sci. Adv. 2020; 6 : eaay3245     1 April 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
8 of 12
of neurological disease signs, it is possible that inhibiting viral rep-
lication in the skin reduced the ability of ZIKV to spread to peripheral 
tissues, including neuronal tissues. However, we cannot exclude the 
possibility that IL-27 may also play a protective role directly in neu-
ronal ZIKV infection or if unknown effects of IL-27 may contribute 
to preventing development of neurological injury during ZIKV infec-
tion. We speculate that intact IL-27 signaling may serve a pivotal 
protective antiviral role in the skin and potentially in the spread from 
the skin to the neuronal systems.
The AVPs OAS1, OAS2, OAS3, OASL, and MX1 have previously 
been shown to be induced primarily by type I IFNs (53). We found 
that IL-27 induces expression of these AVPs in a manner that is 
STAT1 and IL27RA dependent, but STAT2 and IFNAR1 indepen-

























































































































































































































































Hindlimb weakness or disrupted righting reflex
Partial hindlimb weakness or toe knuckling
Complete paralysis of one hindlimb
Unkempt fur
Complete paralysis of two hindlimbs
Moribund or dead
Fig. 6. IL-27 signaling reduces the severity and occurrence of in vivo neurological symptoms due to Zika virus infection in the absence of type I IFN signaling. 
Bar graphs detailing morbidity and mortality of B6 (WT), Ifnar1KO, Il27raKO, and Ifnar1/Il27ra dKO injected subcutaneously with Zika virus (HPF2013 strain) at 5 to 10 days 
after infection. Symptoms were scored in a sequential fashion, where lesser symptoms (e.g., hunched, unkempt fur) were not counted if a mouse presented with more 
severe symptoms (e.g., hindleg weakness). n = 10 to 12 mice (B6), 12 to 14 mice (Il27raKO), 14 to 16 mice (Ifnar1KO), and 11 to 12 mice (Ifnar1/Il27ra dKO) per experimental 
group. Experiment was repeated three times.
Kwock et al., Sci. Adv. 2020; 6 : eaay3245     1 April 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 12
by IL-27 is independent of type I IFN signaling in skin cells, given 
the prominent role of STAT2 and IFNAR1 in classical type I IFN 
induction of ISGs (53). As STAT2 is known to be inhibited by ZIKV 
(44), IL-27 could play a novel host-defensive role to subvert viral 
inhibition of type I IFN regulatory molecules, such as STAT2. siRNA 
knockdown and CRISPR-Cas9 KO of STAT2 resulted in a signifi-
cant increase in IL-27–mediated AVP expression over baseline, which 
may indicate the greater availability of free STAT1 to signal through 
the IL-27–AVP pathway. In further support of the role of IL-27 in 
specifically inducing STAT1 signaling, we found that p-STAT1, but 
not p-STAT2, was rapidly activated in response to IL-27, suggesting 
that IL-27 directly signals through STAT1 to generate AVPs, as op-
posed to indirectly producing AVPs via type I IFN signaling. Together, 
our data indicate that IL-27 is required to generate AVPs in the early 
cutaneous immune response to ZIKV infection via a STAT1- and 
IL27RA-dependent approach. Since IL-27 signaling does not appear 
to require STAT2, an IL-27–based approach would be resistant to 
the STAT2-antagonizing activity of ZIKV (44, 49).
Of note, IRF3 also appeared to play a role in IL-27 signaling. IL-27 
stimulation of human keratinocytes led to rapid nuclear transloca-
tion of IRF3, and knockdown of IRF3 and MAP3K7 (also known as 
TAK1) led to significantly decreased IL-27–mediated OAS2 expres-
sion. A recent study (54) suggested that TAK1 signaling upstream 
of IRF3 leads to nuclear translocation of IRF3 and subsequent pro-
duction of IFN-inducible genes. Although we do not discuss the 
direct interplay between STAT1 and IRF3 here, both genes appear 
to play important roles in IL-27–mediated AVP production.
Further research is needed to delineate the mechanisms behind 
why and how cutaneous IL-27 signaling protects the host from ZIKV 
infection, while systemic IL-27 signaling provides no additional pro-
tection when type I IFN signaling is ablated.
MATERIALS AND METHODS
Contact for reagent and resource sharing
Further information and requests for resources and reagents should 
be directed to and will be fulfilled by the lead contact A.S.M. (amanda.
macleod@duke.edu).
Experimental model and subject details
Key resources can be found in the Supplementary Materials.
Mice
Male and female mice were bred and/or housed in a specific pathogen– 
free facility at the Duke University School of Medicine. For all studies, 
both male and female mice were used. All procedures with animals 
were carried out in strict accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. Protocols were approved by the Duke Univer-
sity Animal Care and Use Committee (Animal Welfare Assurance). 
C57BL6/J, Balb/c, Ifnar1−/−, and Il27ra−/− mice were purchased from 
the Jackson laboratory (Bar Harbor, ME). Stat1−/− and 129S6 mice were 
purchased from Taconic Biosciences. Ifnar1−/− and Il27ra−/− were 
crossbred in Duke’s breeding facility to generate Ifnar1−/− Il27ra−/− 
dKO mice. All mice were used at 4 to 7 weeks of age and were age 
and gender matched for each experiment.
Viruses
Zika virus–Dakar (DAK; Zika virus/A.africanus-tc/SEN/1984/41525-
DAK) (GenBank accession no. KU955591) was used for the in vitro 
experiments in human keratinocytes, and Zika virus–French Polynesia 
(PF; Zika virus strain H/PF/2013) (GenBank accession no. KJ776791.2) 
was used for in vivo infection studies. Strains were provided by 
S. Weaver at the University of Texas Medical Branch and H.L.
(coauthor of this study), respectively. Sendai virus strain Cantell
was obtained from Charles River Laboratory. Zika virus stocks were 
prepared as described (55). All viruses were titered by focus-forming
assay in Vero cells. Vero cells (CCL-81) were obtained from the
American Type Culture Collection (ATCC; Manassas, VA, USA)
and were verified as mycoplasma free by the LookOut Mycoplasma
PCR Detection Kit (Sigma-Aldrich, St. Louis, MO, USA). In vitro Zika 
and Sendai virus infections were performed in serum-free media
conditions for 1 hour, after which human keratinocyte medium
with indicated treatment conditions was replenished.
Percentage of cells infected with Sendai virus quantification
Cells were immunostained for Sendai virus (anti-Sendai, Chicken,
Abcam ab33988) and nuclei [4′,6-diamidino-2-phenylindole (DAPI)], 
and cells were identified as Sendai virus infected or uninfected by
counting Sendai-positive cells using a Cellomics ArrayScan VTI
High Content Screening Reader (Duke Functional Genomics Facility,
Durham, NC, USA). Percentage of infected cells was calculated as
the number of Sendai virus + cells/the number of total cells (Sendai/
DAPI) per field. Values represent the means ± SEM (n = 4 fields)
from three independent experiments, with >3000 cells counted
per field.
Human keratinocytes
Human adult keratinocytes were purchased from Gibco and main-
tained for up to six passages in T-75 flasks. Cells were grown in
37°C serum-free EpiLife cell culture medium with EpiLife Defined
Growth Supplement containing 0.05 mM Ca2+. Keratinocytes were
used at approximately 75 to 80% confluence. For experiments, cells
were plated at 200,000 cells per well in six-well plates, 75,000 cells per
well in 12-well plates, or 75,000 cells per chamber in two-chamber
chamber slides, respectively (Labtek, Grand Rapids, MI).
Method Details
In vivo Zika virus infection
B6, Il27raKO, Ifnar1KO, and Ifnar1/Il27ra dKO mice were injected 
subcutaneously with 103 to 105 Zika virus (HPF2013) once and 
observed for weight, survival, and neurological symptoms over the 
course of 13 to 14 days. For intravenous infections, ZIKV was in-
jected intravenously into the tail vein.
Cytokine stimulation of human keratinocytes
Medium was removed, and new medium containing cytokines was 
used to stimulate keratinocytes for a variety of time points. Unless 
stated otherwise, IL-6, IL-23, IL-27, IL-35 (all from BioLegend), and 
IL-12 (Tonbo) were added to 1 to 2 ml of medium at a concentra-
tion of 100 ng/ml; IFN- (BioLegend) or IFN- (PeproTech) was 
added to 1 to 2 ml of media at a concentration of 50 U/ml. For the 
cytotoxicity study, cells were suspended in CellTiter 96 AQueous 
One Solution Reagent and then incubated at 37°C for 1 to 4 hours 
in a humidified, 5% CO2 atmosphere. Absorbance was read at 
490 nm using a 24-well plate reader.
TLR and PRR ligand stimulation of human keratinocytes
Medium was removed, and new medium containing cytokines was 
used to stimulate keratinocytes for a variety of time points. Poly I:C 
LMW, 5′PPPdsRNA, 5′PPPdsRNA control, cGAMP, and imiquimod 
were obtained from InvivoGen. Unless stated otherwise, TLR and 
PRR ligands were added to 1 to 2 ml of medium at a concentration 
of 100 ng/ml.
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Immunofluorescence staining
Briefly, human primary keratinocytes were grown to subconfluency 
before IL-27 stimulation. For MX1 staining, cells were fixed with 100% 
ice-cold methanol and incubated in a blocking solution of 1×Dulbecco’s 
Phospate Buffered Saline (DPBS) containing 2.5% normal goat serum 
(Jackson ImmunoResearch), 2.5% normal donkey serum (Jackson 
ImmunoResearch), 1% bovine serum albumin (Calbiochem), 2% fish 
gelatin (Sigma), and 0.1% Triton X-100 (Sigma) for 1 hour at room 
temperature. Then, cells were incubated with anti-MX1 antibody 
(Abcam; final concentration 0.060 mg/ml) or appropriate immu-
noglobulin G (IgG) controls in a solution of fresh blocking solution 
and 0.1% Triton X-100 (mixed at a ratio 1:1) for 2 hours at room 
temperature. After the washing steps, cells were incubated with 
an Alexa Fluor 555–conjugated secondary antibody (Thermo Fisher 
Scientific Jackson). After subsequent washing, nuclei were counter-
stained with Hoechst 33342 (Thermo Fisher Scientific), washed in 
1×DPBS, and mounted with ProLong Gold antifade reagent (Thermo 
Fisher Scientific). For OAS2 staining, stimulated keratinocytes were 
paraformaldehyde (PFA) fixed (4% PFA) and incubated in a blocking 
solution of 1×DPBS containing 5% normal goat serum (Jackson 
ImmunoResearch) and 0.1% Triton X-100 for 1 hour at room tem-
perature before incubation with anti-OAS2 antibody (Proteintech 
0.33 mg/ml) or appropriate IgG control in 1% bovine serum albumin 
with 0.1% Triton X-100 for 2 hours at room temperature. Second-
ary antibody and Hoechst staining are described above. For staining 
with p-STAT1, p-STAT2, and IRF3, cells were fixed in 4% PFA 
followed by ice-cold methanol, washed, and stained with rabbit 
polyclonal anti-pSTAT1, anti-pSTAT2, or anti-IRF3 antibodies (all 
from Cell Signaling Technologies). After subsequent washes, cells 
were incubated with secondary Cy3-conjugated goat anti-rabbit an-
tibody (Life Technologies) before Hoechst staining and mounting.
Focus-forming assay
Supernatants were collected at 48 hours postinfection or after from 
sera of infected mice and stored at −80°C until virus titration. Serial 
dilutions of thawed supernatants and sera were used to infect naïve 
Vero cells in triplicate wells of a 48-well plate. At 1 hour postinfec-
tion, Vero cells were overlaid with 2% methylcellulose and 2% fetal 
bovine serum in Opti-MEM. At 72 hours postinfection, cells were 
fixed in a 1:1 methanol/acetone solution and immunostained with 
mouse anti-4G2 antibody (1:500), generated from the D1-4G2-4-15 
hybridoma cell line against flavivirus envelope protein (ATCC). 
Following binding of horseradish peroxidase–conjugated secondary 
antibody (Jackson ImmunoResearch, 1:500), infected foci were 
visualized with the VIP Peroxidase Substrate Kit (Vector Laboratories) 
and counted at ×40 magnification to determine the viral titer 
(focus-forming units per milliliter).
RNA isolation and qRT-PCR
For murine ear tissue, epidermal ear sheets were separated and 
floated on trypsin GNK for 15 min at 37°C. Then, two curved for-
ceps were used to separate the epidermis from the dermis of each 
ear sheet, and both layers of skin were then homogenized using scis-
sors and placed into TRIzol for quantitative PCR (qPCR) analysis. 
Total RNA was isolated using a Direct-zol Kit (Genesee Scientific, 
Research Triangle Park, NC) or using TRIzol reagent (Invitrogen). 
RNA was reverse transcribed using the iScript cDNA Synthesis Kit 
(Bio-Rad, Hercules, CA), and the resulting cDNA was amplified 
using Fast SYBR Green Master Mix (Applied Biosystems). Primers for 
amplification are listed in table S1 online. Fold induction of gene ex-
pression was normalized to the house keeping glyceraldehyde-3- 
phosphate dehydrogenase and calculated using the 2(−Ct) 
method.
siRNA knockdown
siRNA constructs were obtained from either Dharmacon or OriGene. 
siRNA transfection buffer and transfection reagent were obtained 
from OriGene. Cells were plated 1 day before transfection, and medium 
was changed to serum-free medium 2 hours before transfection. 
siRNA constructs were resuspended in 1× transfection buffer at a 
concentration of 0.02 nmol/l. Each construct (1.7 l) was added 
to a 200-l master mix that contained both 1× transfection buffer 
and transfection reagent at volumes indicated by the manufacturer. 
siRNA master mixes were allowed to incubate at room temperature 
for 15 to 30 min before being added dropwise to wells. Five hours 
after siRNA master mixes were added, media were changed to serum- 
containing medium, and cells were stimulated with the indicated 
cytokines as described above.
Quantification and statistical analysis
Statistical analysis
Analyses of all in vitro and in vivo experiments were conducted 
using Prism software and depicts means ± SEM. Data are presented 
as means ± SEM. Group sizes were determined on the basis of the 
results of preliminary experiments without predetermination of 
sample size. Preliminary experiments were performed to determine 
requirements for sample size, taking into account resources avail-
able and ethical, reductionist animal use. Mice were randomly 
assigned to groups. Mouse studies were not performed in a blinded 
fashion. Generally, each mouse of the different experimental groups 
was reported. Statistical analysis was calculated using Prism software 
(GraphPad), with significance reported for P < 0.05 and is detailed 
in the figure legends.
Microarray data analysis and computation
Human Affymetrix microarray data were processed and normal-
ized using the affy (56) and limma (57) Bioconductor (58) packages 
from the R statistical programming environment. Raw data were 
normalized to eliminate systematic differences across samples using 
the robust multiarray average approach, and differential expression 
between IL-27 stimulated and control samples was calculated using 
a linear model with an empirical Bayes’ estimation of the test statistic. 
The false discovery rate was used to correct for multiple hypothesis 
testing.
Data and software availability
Data showing the IL-27 stimulated human keratinocyte dataset 
(shown in Figure 1) can be found at GSE143228.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/14/eaay3245/DC1
View/request a protocol for this paper from Bio-protocol.
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